The Family Firm’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-3,511
| Closed | -$98.2K | – | 661 |
|
|
2024
Q2 | $98.2K | Buy |
+3,511
| New | +$96.7K | 0.02% | 278 |
|
|
2023
Q4 | – | Sell |
-13,990
| Closed | -$464K | – | 190 |
|
|
2023
Q3 | $464K | Buy |
13,990
+24
| +0.2% | +$849 | 0.13% | 104 |
|
|
2023
Q2 | $512K | Buy |
13,966
+17
| +0.1% | +$662 | 0.14% | 100 |
|
|
2023
Q1 | $569K | Buy |
13,949
+9
| +0.1% | +$389 | 0.16% | 95 |
|
|
2022
Q4 | $714K | Sell |
13,940
-5,984
| -30% | -$287K | 0.21% | 84 |
|
|
2022
Q3 | $872K | Buy |
19,924
+1,410
| +8% | +$68.5K | 0.28% | 69 |
|
|
2022
Q2 | $971K | Buy |
18,514
+14,496
| +361% | +$739K | 0.29% | 68 |
|
|
2022
Q1 | $208K | Buy |
4,018
+130
| +3% | +$6.75K | 0.05% | 173 |
|
|
2021
Q4 | $230K | Buy |
+3,888
| New | +$193K | 0.06% | 171 |
|
|
2019
Q3 | – | Sell |
-5,780
| Closed | -$238K | – | 145 |
|
|
2019
Q2 | $238K | Buy |
5,780
+8
| +0.1% | +$318 | 0.08% | 127 |
|
|
2019
Q1 | $233K | Sell |
5,772
-792
| -12% | -$31.7K | 0.08% | 128 |
|
|
2018
Q4 | $272K | Buy |
6,564
+7
| +0.1% | +$291 | 0.11% | 111 |
|
|
2018
Q3 | $274K | Sell |
6,557
-79
| -1% | -$3.04K | 0.1% | 117 |
|
|
2018
Q2 | $228K | Sell |
6,636
-759
| -10% | -$25.9K | 0.09% | 121 |
|
|
2018
Q1 | $249K | Sell |
7,395
-1,988
| -21% | -$68.3K | 0.1% | 116 |
|
|
2017
Q4 | $322K | Buy |
9,383
+19
| +0.2% | +$648 | 0.13% | 96 |
|
|
2017
Q3 | $317K | Sell |
9,364
-60
| -0.6% | -$1.93K | 0.13% | 92 |
|
|
2017
Q2 | $300K | Buy |
9,424
+659
| +8% | +$20.8K | 0.13% | 95 |
|
|
2017
Q1 | $284K | Buy |
8,765
+122
| +1% | +$3.85K | 0.14% | 89 |
|
|
2016
Q4 | $266K | Sell |
8,643
-12
| -0.1% | -$366 | 0.13% | 94 |
|
|
2016
Q3 | $278K | Buy |
8,655
+181
| +2% | +$6.05K | 0.13% | 88 |
|
|
2016
Q2 | $283K | Buy |
8,474
+15
| +0.2% | +$479 | 0.14% | 88 |
|
|
2016
Q1 | $238K | Buy |
8,459
+500
| +6% | +$14.3K | 0.12% | 91 |
|
|
2015
Q4 | $244K | Sell |
7,959
-344
| -4% | -$10.8K | 0.13% | 90 |
|
|
2015
Q3 | $247K | Buy |
8,303
+14
| +0.2% | +$449 | 0.13% | 85 |
|
|
2015
Q2 | $264K | Buy |
8,289
+951
| +13% | +$31K | 0.14% | 85 |
|
|
2015
Q1 | $242K | Buy |
7,338
+8
| +0.1% | +$254 | 0.12% | 91 |
|
|
2014
Q4 | $217K | Buy |
+7,330
| New | +$210K | 0.11% | 98 |
|
Other funds holding PFE
The Family Firm's PFE Position: Q3 2024 in Review
The Family Firm sold out of Pfizer (PFE) in Q3 2024, closing a stake of 3,511 shares — an estimated $98.2K sold.
The Family Firm first reported a position in PFE in Q4 2014 and held it in 28 quarters. The position peaked at $971K in Q2 2022. 2,910 funds tracked by Wall St. Rank hold PFE as of Q3 2024.
- The Family Firm reported no remaining Pfizer position as of Q3 2024 after selling out during the quarter.
- The Family Firm sold 3,511 Pfizer shares in Q3 2024, an estimated $98.2K.
- The Family Firm first reported a position in Pfizer in Q4 2014 and held it in 28 quarters.
- The Family Firm's Pfizer position peaked at $971K in Q2 2022.
- 2,910 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.
Based on The Family Firm's 13F filing for Q3 2024, filed 17 Oct 2024.